Pancreatic alpha cells and glucagon secretion : Novel functions and targets in glucose homeostasis
Wendt, Anna LU and Eliasson, Lena LU
(2022)
In Current Opinion in Pharmacology
63.
- Abstract
Diabetes is the result of dysregulation of both insulin and glucagon. Still, insulin has attracted much more attention than glucagon. Glucagon is released from alpha cells in the islets of Langerhans in response to low glucose and certain amino acids. Drugs with the primary aim of targeting glucagon signalling are scarce. However, glucagon is often administered to counteract severe hypoglycaemia, and commonly used diabetes medications such as GLP-1 analogues, sulfonylureas and SGLT2-inhibitors also affect alpha cells. Indeed, there are physiological and developmental similarities between the alpha cell and the insulin-secreting beta cell and new data confirm that alpha cells can be converted into insulin-secreting cells. These aspects... (More)
Diabetes is the result of dysregulation of both insulin and glucagon. Still, insulin has attracted much more attention than glucagon. Glucagon is released from alpha cells in the islets of Langerhans in response to low glucose and certain amino acids. Drugs with the primary aim of targeting glucagon signalling are scarce. However, glucagon is often administered to counteract severe hypoglycaemia, and commonly used diabetes medications such as GLP-1 analogues, sulfonylureas and SGLT2-inhibitors also affect alpha cells. Indeed, there are physiological and developmental similarities between the alpha cell and the insulin-secreting beta cell and new data confirm that alpha cells can be converted into insulin-secreting cells. These aspects and attributes, the need to find novel therapies targeting the alpha cell and more are considered in this review.
(Less)
- author
- Wendt, Anna
LU
and Eliasson, Lena
LU
- organization
- publishing date
- 2022-04
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Current Opinion in Pharmacology
- volume
- 63
- article number
- 102199
- publisher
- Elsevier
- external identifiers
-
- pmid:35245797
- scopus:85125705353
- ISSN
- 1471-4892
- DOI
- 10.1016/j.coph.2022.102199
- language
- English
- LU publication?
- yes
- id
- 61317b68-9768-4909-9f04-4f190f9339ac
- date added to LUP
- 2022-04-14 10:56:56
- date last changed
- 2024-06-21 04:27:34
@article{61317b68-9768-4909-9f04-4f190f9339ac,
abstract = {{<p>Diabetes is the result of dysregulation of both insulin and glucagon. Still, insulin has attracted much more attention than glucagon. Glucagon is released from alpha cells in the islets of Langerhans in response to low glucose and certain amino acids. Drugs with the primary aim of targeting glucagon signalling are scarce. However, glucagon is often administered to counteract severe hypoglycaemia, and commonly used diabetes medications such as GLP-1 analogues, sulfonylureas and SGLT2-inhibitors also affect alpha cells. Indeed, there are physiological and developmental similarities between the alpha cell and the insulin-secreting beta cell and new data confirm that alpha cells can be converted into insulin-secreting cells. These aspects and attributes, the need to find novel therapies targeting the alpha cell and more are considered in this review.</p>}},
author = {{Wendt, Anna and Eliasson, Lena}},
issn = {{1471-4892}},
language = {{eng}},
publisher = {{Elsevier}},
series = {{Current Opinion in Pharmacology}},
title = {{Pancreatic alpha cells and glucagon secretion : Novel functions and targets in glucose homeostasis}},
url = {{http://dx.doi.org/10.1016/j.coph.2022.102199}},
doi = {{10.1016/j.coph.2022.102199}},
volume = {{63}},
year = {{2022}},
}